Payment overview · 2025
General Payments
$1,755.60
65 reported records · 35 companies
Healthcare provider profile · identity verified
Anilkumar N Raiker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ST PETERSBURG, FL · NPI 1487616017
Verified facts
What the public records show
CMS Open Payments records show Anilkumar N Raiker, M.D. received $1,755.60 in general payments during 2025 across 65 reported records.
Novartis Pharmaceuticals Corporation accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kisqali, Verzenio.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verzenio by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kisqali by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $351.90 | 20.0% | 8 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $107.97 | 6.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.07 | 5.1% | 4 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $73.75 | 4.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.66 | 4.1% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $71.45 | 4.1% | 3 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $61.95 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $58.28 | 3.3% | 3 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.02 | 3.2% | 2 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $52.09 | 3.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $51.55 | 2.9% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $48.16 | 2.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.37 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.39 | 2.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.79 | 2.1% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $37.16 | 2.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $31.89 | 1.8% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $31.89 | 1.8% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $31.62 | 1.8% | 1 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $31.18 | 1.8% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $30.56 | 1.7% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $29.51 | 1.7% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $28.57 | 1.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.13 | 1.6% | 1 | 2025 |
| Immunocore Limited | Unresolved — no canonical attribution shown | $27.82 | 1.6% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $26.81 | 1.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.75 | 1.5% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $24.87 | 1.4% | 1 | 2025 |
| Fennec Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.74 | 1.4% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.33 | 1.4% | 1 | 2025 |
| Menarini Silicon Biosystems, Inc. | Unresolved — no canonical attribution shown | $23.12 | 1.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.71 | 1.2% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.91 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.97 | 1.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $13.66 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,505.61 | 62 |
| Long term medical supply or device loan | $249.99 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $270.03 | 5 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $107.97 | 4 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $76.36 | 4 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $74.78 | 3 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $73.75 | 3 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $73.75 | 3 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $61.95 | 2 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $57.02 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $57.02 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $57.02 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $54.25 | 2 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $52.09 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $51.55 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $51.55 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $51.45 | 3 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $50.95 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $48.16 | 2 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $47.37 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $37.16 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $31.89 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $31.62 | 1 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $31.18 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $30.56 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| KIMMTRAK Normalized: kimmtrak |
Drug | Immunocore Limited | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| Fyarro Normalized: fyarro |
Drug | Fennec Pharmaceuticals, Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | Menarini Silicon Biosystems, Inc. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| KISQALI kisqali |
2025 | Kisqali | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Anastrozole | Anastrozole | 54 | 23 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Kisqali | Ribociclib Succinate | 13 | suppressed |
| Verzenio | Abemaciclib | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,755.60 · 65 records | Novartis Pharmaceuticals Corporation | AKEEGA, BALVERSA, BESREMI, BRAFTOVI, BRUKINSA, CARVYKTI, Cellsearch, ENJAYMO, ERLEADA, Enhertu, FOTIVDA, FRUZAQLA, Fabhalta, Fyarro, Gavreto, IBRANCE, IMFINZI, INLYTA, JAKAFI, JAYPIRCA, KIMMTRAK, KISQALI, LIBTAYO, LORBRENA, Lenvima, MEKTOVI, NINLARO, OJJAARA, OPDIVO, ORGOVYX, Orserdu, PADCEV, PLUVICTO, REBLOZYL, Rezlidhia, SARCLISA, TAVALISSE, TUKYSA, Tyenne, ULTOMIRIS, VENCLEXTA, VERZENIO, Vonjo, XPOVIO, XT CDX, XTANDI, Yescarta | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kisqali play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error